Johnsson Nordic ACT 2013.

Methods	Phase III open‐label RCT; n = 249
Participants	People with mCRC after finishing first‐line treatment with combined chemotherapy and bevacizumab
Interventions	Combined erlotinib and bevacizumab vs bevacizumab
Outcomes	Primary outcome: PFS. Secondary outcomes: OS, toxicity
Notes	Supported by Roche Sweden, Futurum ‐ the Academy for Healthcare, Jonkoping County Council, and by the Skane Regional Council. Johnsson: presentation honoraria from Genentech. Follow‐up 36.8 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised 1:1 ‐ no further information
Allocation concealment (selection bias)	Unclear risk	No further information
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	High risk	No independent radiology review was done.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcome reported when 131/159 participants progressed; 6 participants (4 interventional, 2 control arms) withdrawn due to aim for curative surgery.
Selective reporting (reporting bias)	Low risk	All outcomes reported.
Other bias	Low risk	No other significant bias present; funders did not have inappropriate influence.